<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102447">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01794260</url>
  </required_header>
  <id_info>
    <org_study_id>AFTA-01</org_study_id>
    <nct_id>NCT01794260</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Topical Essential Oil Extracted From Zingiber Cassumunar Rokb in Osteoarthritis</brief_title>
  <official_title>Efficacy and Safety of Topical Preparation of Essential Oil Extracted From Zingiber Cassumunar Rokb in Patients With Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess short term efficacy and safety of of topical
      preparation of essential oil extracted from ZINGIBER CASSUMUNAR ROXB in  patients suffering
      from  osteoarthritic pain
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline of The WOMAC (Western Ontario and McMaster Universities) index</measure>
    <time_frame>week 8</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Pain visual analog scale (PVAS)</measure>
    <time_frame>week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Global assessment of disease status (GADS)</measure>
    <time_frame>week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical global impression of change (CGIC)</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global impression of change (PGIC)</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Placebo cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plai cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cream from Zingiber cassumunar Roxb. extract</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cream from  Zingiber cassumunar Roxb. extract</intervention_name>
    <arm_group_label>Plai cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo cream</intervention_name>
    <arm_group_label>Placebo cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis: osteoarthritis of the knee at least on side with standard radiologic
             method within 6 weeks (Kellgren-Lawrence radiographic grading scale at least 1)

          -  Pain visual analog scale at rest at least 40 mm

          -  No previous analgesic treatment or receiving stable dose of analgesic drugs at least
             2 weeks. If previously treated with antidepressants, glucosamine, chondroitin or
             diacerein, dosage should be stable for at least 3 months.

          -  Agree to attain non-pharmacologic treatment as prior to participate the study

        Exclusion Criteria:

          -  having an open wound or abnormal skin at site of application

          -  having diagnose with other chronic arthritis such as rheumatoid arthritis

          -  history of allergy to the extraction of Zingiber cassumunar Roxb

          -  pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chuthamanee Suthisisang, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Pharmacology, Faculty of Pharmacy, Mahidol University 447 Sri-Ayudhya Rd., Rajthevee, Bangkok 10400, Thailand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suwimon Yeephu, M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Pharmacy, Srinakharinwirot University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chuthamanee Suthisisant, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chuthamanee Suthisisang, Ph.D.</last_name>
    <phone>662-644-8700</phone>
    <email>pycst@mahidol.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suwimon Yeephu, M.Sc.</last_name>
    <phone>6686-9836644</phone>
    <email>suwimony@swu.ac.th</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, Srinakharinwirot University</name>
      <address>
        <city>Ongkarak</city>
        <state>Nakhonnayok</state>
        <zip>26120</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuthamanee Suthisisang, Ph.D</last_name>
      <phone>662-644-8700</phone>
      <email>pycst@mahidol.ac.th</email>
    </contact>
    <contact_backup>
      <last_name>Suwimon Yeephu, M.Sc.</last_name>
      <phone>6686-9836644</phone>
      <email>suwimony@swu.ac.th</email>
    </contact_backup>
    <investigator>
      <last_name>Suwimon Yeephu, M.Sc.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>February 14, 2013</lastchanged_date>
  <firstreceived_date>December 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Moderate ot severe pain</keyword>
  <keyword>ZINGIBER CASSUMUNAR ROXB</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
